NPM1 and acute myeloid leukemia: We identified which leukemia-associated antigen (LAA) stimulated the largest IFNγ immune response by T cells from AML patients with and without the nucleophosmin 1 (NPM1) mutation and which immunotherapeutic strategy, either alone or in combination with the immune checkpoint anti-PD-1, could enhance immune responses against leukemic cells.